Terminated PHASE2 INTERVENTIONAL 1-arm NCT00104884

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma

Sponsor: ECOG-ACRIN Cancer Research Group

Updated 7 times since 2017 Last updated: Jun 13, 2023 Started: Oct 4, 2005 Primary completion: May 31, 2006 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated on May 17, 2006 due to slow accrual.

Other terminated trials from ECOG-ACRIN Cancer Research Group

More terminations from ECOG-ACRIN Cancer Research Group

Other Malignant Melanoma trials with similar outcome

Browse all Malignant Melanoma trials

A PHASE2 clinical study on Malignant Melanoma and Melanoma, this trial is terminated or withdrawn. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jul 2023 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2023 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.